Skip to main content

Peer Review reports

From: Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Original Submission
21 Nov 2017 Submitted Original manuscript
20 Dec 2017 Author responded Author comments - Lee Schwartzberg
Resubmission - Version 2
20 Dec 2017 Submitted Manuscript version 2
15 Mar 2018 Reviewed Reviewer Report - Sunita Ghosh
18 Apr 2018 Reviewed Reviewer Report - Galina Velikova
31 Aug 2018 Author responded Author comments - Lee Schwartzberg
Resubmission - Version 3
31 Aug 2018 Submitted Manuscript version 3
9 Oct 2018 Reviewed Reviewer Report - Galina Velikova
10 Jan 2019 Reviewed Reviewer Report - Paul Henri Cottu
28 Feb 2019 Author responded Author comments - Lee Schwartzberg
Resubmission - Version 4
28 Feb 2019 Submitted Manuscript version 4
27 Mar 2019 Author responded Author comments - Lee Schwartzberg
Resubmission - Version 5
27 Mar 2019 Submitted Manuscript version 5
10 Apr 2019 Author responded Author comments - Lee Schwartzberg
Resubmission - Version 6
10 Apr 2019 Submitted Manuscript version 6
Publishing
3 May 2019 Editorially accepted
13 Jun 2019 Article published 10.1186/s12885-019-5674-5

You can find further information about peer review here.

Back to article page